Rectal Morbidity Following I-125 Prostate Brachytherapy in Relation to Dosimetry
Open Access
- 25 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 37 (2) , 121-126
- https://doi.org/10.1093/jjco/hyl133
Abstract
To investigate rectal morbidity after I-125 prostate brachytherapy and to analyze predictive factors of rectal morbidity. A group of 227 consecutive patients with localized prostate cancer were treated with I-125 prostate brachytherapy with or without external beam radiotherapy (EBRT) between September 2003 and January 2005. Rectal morbidity (diarrhea, bleeding and pain) was evaluated using the Radiation Therapy Oncology Group (RTOG) criteria. Dosimetry was based on computerized tomography (CT) scan 1 month post-implant. The clinical, treatment-related and dosimetric factors were evaluated for the risk of grade 2 rectal morbidity. Rectal dosimetric factors included the rectal volume that received >100% and 150% of the prescribed dose, and the maximal rectal dose which was defined as the sum of the minimal dose received by 1% of the rectum volume and the prescribed dose of EBRT. Grade 2 rectal bleeding occurred in 10 (4.4%): for nine patients within the first year and for one patient between the first and second year. Grade 2 diarrhea occurred in one patient (0.4%) within the first year. No patient reported grade 2 pain. In the univariate analysis with grade 2 rectal bleeding, there were significant correlations with number of seeds, supplemental EBRT, and all of the rectal dosimetric parameters. On subsequent multivariate analysis, the only significant factor was the maximal rectal dose (P < 0.001). Rectal dose > 160 Gy was correlated to grade 2 rectal morbidity. All the patients with rectal dose > 160 Gy received EBRT. Manifestations of rectal morbidity are acceptable events after I-125 prostate brachytherapy. Rectal dose–volume histogram for the brachytherapy is a predictive method for assessing the risk of developing grade 2 rectal bleeding. Delivery of the rectal dose should not exceed 160 Gy in order to avoid rectal complications.Keywords
This publication has 16 references indexed in Scilit:
- Predictive Factors of Acute Urinary Retention Requiring Catheterization Following 125I Prostate BrachytherapyJapanese Journal of Clinical Oncology, 2006
- Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictorsInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Rectal fistulas after prostate brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Acute urinary morbidity following I-125 prostate brachytherapyInternational Journal of Clinical Oncology, 2005
- Probability of late rectal morbidity in 125I prostate brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Defining the risk of developing Grade 2 proctitis following 125I prostate brachytherapy using a rectal dose–volume histogram analysisInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Rectal complications associated with transperineal interstitial brachytherapy for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Palladium-103 brachytherapy for prostate carcinomaPublished by Elsevier ,2000
- Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinomaCancer, 1998